NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market on Monday that its third-quarter revenues increased 42 percent, driven by a sharp uptick in molecular diagnostics sales.

The Salt Lake City-based firm generated revenues of $87.5 million for the three-month period ended Mar. 31, compared to $61.8 million for the first quarter of 2008. Its molecular diagnostics sales were $86.5 million, up from $59 million in Q1 2008, while its research and other revenue fell to just under $1 million from $2.7 million the year before.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.